SEC Comment Letter 0000000000-25-011798 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: Dec. 23, 2025 · CIK: 0000890821 · Accession: 0000000000-25-011798
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292363
Letter
December 23, 2025 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 245 First Street, Riverview II, 18th Floor Cambridge, MA 02142 Re:Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed December 22, 2025 File No. 333-292363 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Bradley J. Wyatt, Esq.
Show Raw Text
December 23, 2025
Joseph Tucker
Chief Executive Officer
Enveric Biosciences, Inc.
245 First Street, Riverview II, 18th Floor
Cambridge, MA 02142
Re:Enveric Biosciences, Inc.
Registration Statement on Form S-3
Filed December 22, 2025
File No. 333-292363
Dear Joseph Tucker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Bradley J. Wyatt, Esq.